Table 1 Baseline characters of patients enrolled in this study
Variable | Training cohort | Validation cohort |
|---|---|---|
Total number | 166 | 42 |
Gender | ||
 Male | 101 (60.8%) | 19 (45.2%) |
 Female | 65 (39.2%) | 23 (54.8%) |
 Age at diagnosis (years) | 45 (14–72)a | 44 (19–68) a |
  < 45 | 88 (53.0%) | 18 (42.9%) |
  ≥ 45 | 78 (47.0%) | 24 (57.1%) |
Tumor side | ||
 Left | 71 (42.8%) | 21 (50.0%) |
 Right | 87 (52.4%) | 17 (40.5%) |
 Bilateral | 7 (4.2%) | 4 (9.5%) |
Frontal lobe involvement | ||
 Involved | 105 (63.3%) | 27 (64.3%) |
 None | 61 (36.7%) | 15 (35.7%) |
Temporal lobe involvement | ||
 Involved | 73 (44.0%) | 13 (31.0%) |
 None | 93(56.0%) | 29 (69.0%) |
Neuro-function deficit | ||
 Yes | 46 (27.7%) | 16 (38.1%) |
 No | 120 (72.3%) | 26 (61.9%) |
Preoperative GRE | ||
 GRE | 62 (37.3%) | 15 (35.7%) |
 Non-GRE | 104 (62.7%) | 27 (64.3%) |
Postoperative GRE | ||
 GRE | 30 (18.1%) | 7 (16.7%) |
 Non-GRE | 136 (81.9%) | 35 (83.3%) |
EOR | ||
 GTR | 81 (48.8%) | 26 (61.9%) |
 Non-GTR | 85 (51.2%) | 16 (38.1%) |
WHO grade | ||
 3 | 99 (59.6%) | 27(64.3%) |
 4 | 67 (40.4%) | 15 (35.7%) |
Tumor pathology | ||
 AA | 68 (41.0%) | 15 (35.7%) |
 AO | 31 (18.7%) | 12 (28.6%) |
 GBM | 67 (40.3%) | 15 (35.7%) |
IDH1/2 mutation | ||
 Mutation | 83 (50.0%) | 26(61.9%) |
 Wild type | 83(50.0%) | 16 (38.1%) |
Chromosome 1p/19q codeletion†| ||
 Codeletion | 42 (25.3%) | 13 (31.0%) |
 Non-codeletion | 111 (66.9%) | 28 (69.0%) |
MGMT promoter‡ | ||
 methylated | 81 (48.8%) | 22 (52.4%) |
 unmethylated | 61 (36.7%) | 17 (40.5%) |
Concurrent Radio-chemotherapy | ||
 Yes | 124 (74.7%) | 29 (69.0%) |
 No | 39 (23.5%) | 13 (31.0%) |